Vertex Is a Rare-Disease Powerhouse
November 13, 2017 at 07:00 AM EST
The shares currently look undervalued ahead of further drug approval.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions. |